The outlook of companies tied to Viagra's past presents a complex investment scenario . While the initial success generated substantial gains, generic alternatives have significantly impacted revenue. Investing in connected pharmaceutical firms now requires a careful assessment of patent rights , evolving medical changes, and the prospect for innov